NCT05637281

Clinical Efficacy of Indomethacin in Early Treatment of Acute Pancreatitis

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 188 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Acute pancreatitis is a common critical disease of the digestive system. Accumulated data showed that overexpression of cyclooxygenase-2 (COX-2) in acute pancreatitis and experimental pancreatitis could be attenuated with COX-2 inhibitors. In recent years, it has been found that timely administration of indomethacin or diclofenac sodium to anus after ERCP can significantly reduce the incidence of AP after ERCP in patients at high risk of AP. The aim of this study was to evaluate the efficacy of rectal indomethacin in reducing the systemic inflammatory response syndrome (SIRS) score in AP patients.

Conditions

• Acute Pancreatitis
• Systemic Inflammatory Response Syndrome

Interventions

Type	Name	Description
DRUG	Indometacin	Besides the conventional treatment, indomethacin will be given to the patients in the convention + indomethacin group.
OTHER	conventional treatment	All enrolled patients received conventional management according to AP guidelines of International Association of Pancreatology and the Chinese Society of Gastroenterology, including goal-directed fluid resuscitation, oxygen supply even mechanical ventilation, and nutritional support if necessary.

Timeline

• Start date: 2022-12-11
• Primary completion: 2023-12-11
• Completion: 2023-12-11
• First posted: 2022-12-05
• Last updated: 2023-02-17

Locations

1 site across 1 country: China